Summary

71.81 0.99(1.40%)07/10/2025
AstraZeneca PLC (AZN)

Key Facts


1 Day1 Week1 Month3 Months6 Months1 Year5 Years
1.403.40-2.7410.708.67-5.7950.96


Last 730 data points are shown. To view all data, Upgrade to PRO plan!


Fundamental Ratings
CategoryRating
Main RatingB
Recommended RatingNeutral
DCFBuy
ROEStrong Buy
ROABuy
Debt/EquityStrong Sell
P/EStrong Sell
P/BStrong Sell


Earnings
  • AZN reported last earnings on 2025-04-29 after the market.
  • An EPS of $1.24 was observed compared to an estimated EPS of $1.1, resulting in a surprise value of $0.14.
  • A revenue of $13,588 million was observed compared to an estimated revenue of $14,058 million, resulting in a surprise value of $-470 Million.


  • Trading Data
    Close71.81
    Open71.65
    High72.46
    Low71.29
    Volume4,042,918
    Change0.99
    Change %1.40
    Avg Volume (20 Days)4,129,782
    Volume/Avg Volume (20 Days) Ratio0.98
    52 Week Range61.81 - 86.47
    Price vs 52 Week High-16.95%
    Price vs 52 Week Low16.18%
    Range0.00
    Gap Up/Down0.78
    Profitibility
    Market Capitalization (Mln)432,660
    Revenue per share17.7361
    Net Income per share2.5071
    Dividend Yield0.0214
    Dividend Share154.00%
    Valuations
    Enterprise Value0.00%
    PE Ratio57.2854
    PB Ratio0.0000
    PTB Ratio0.0000
    Liquidity
    Debt/Equity Ratio0.0000
    Net Debt/EBIDTA Ratio0.0000
    Current Ratio0.0000
    Enterprise Value and Cash Flow
    EV/Sales Ratio0.0000
    EV/EBIDTA Ratio0.0000
    EV/Free Cash Flow Ratio0.0000


    07/10 09:47 EST - proactiveinvestors.co.uk
    Trumps 200% tariffs. Here's what it means for UK pharma investors
    UBS has flagged a fresh risk for European drugmakers after President Trump said pharmaceuticals imported into the US could soon face tariffs of up to 200%. The comments, made earlier this week, revive concerns over protectionist policies targeting medicines not manufactured on American soil.
    07/09 09:46 EST - proactiveinvestors.co.uk
    AstraZeneca: Market isn't pricing in the potential of late-stage pipeline, says bank
    If you're looking for a solid growth story in the pharma sector, AstraZeneca PLC (LSE:AZN) should be on your radar. Berenberg's latest update paints a bright picture, highlighting some exciting pipeline readouts that haven't yet made their way into the share price.
    07/08 11:46 EST - zacks.com
    AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?
    AstraZeneca  AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 billion in sales.
    07/08 07:00 EST - seekingalpha.com
    AstraZeneca: Just What The Doctor Ordered
    AstraZeneca is a classic GARP stock with robust growth, an undervalued share price, and a strong drug pipeline supporting future earnings expansion. Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations, and key therapy areas like oncology and respiratory are driving...
    07/04 09:36 EST - zacks.com
    AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer
    AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.
    07/04 05:10 EST - seekingalpha.com
    Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain
    Summit Therapeutics is in advanced talks with AstraZeneca for a potential $15B licensing deal for ivonescimab, boosting its cash runway and strategic position. Ivonescimab shows strong PFS data versus Keytruda in NSCLC, but mixed OS results could delay U.S. approval and complicate regulatory...
    07/04 03:15 EST - proactiveinvestors.co.uk
    AstraZeneca wins EU approval for Imfinzi in early bladder cancer treatment
    AstraZeneca PLC's (LSE:AZN) cancer drug Imfinzi has been approved in the European Union for use before and after surgery in patients with muscle-invasive bladder cancer, marking a significant step forward in treatment options for the disease. The approval means Imfinzi is now the first and only...
    07/03 18:26 EST - fool.com
    Why AstraZeneca Stock Got Thumped on Thursday
    AstraZeneca (AZN -2.36%) might soon be on the hook for an eventual 11-figure payout, and investors weren't all that comfortable with this. A Bloomberg article published Thursday morning said that the company is pursuing what might end up being an expensive partnership with a biotech.
    07/03 11:38 EST - youtube.com
    Report: Summit in talks for $15 billion partnership with AstraZeneca
    CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on AstraZeneca
    07/02 10:47 EST - invezz.com
    AstraZeneca exit: here's what it really means for the UK
    AstraZeneca Plc (LON: AZN) is in focus this morning following reports that its chief executive – Pascal Soriot is considering moving the giant's listing to the US.
    07/02 09:51 EST - zacks.com
    Why Investors Need to Take Advantage of These 2 Medical Stocks Now
    Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
    07/02 09:02 EST - proactiveinvestors.co.uk
    Are these the UK's top income stocks? One leading bank thinks so
    Reliable income stocks are a staple of a balanced portfolio. But according to research from UBS, the UK has only a handful that warrant close attention.
    07/01 19:16 EST - zacks.com
    Astrazeneca (AZN) Advances While Market Declines: Some Information for Investors
    Astrazeneca (AZN) reached $71.46 at the closing of the latest trading day, reflecting a +2.26% change compared to its last close.
    07/01 17:18 EST - fool.com
    Why AstraZeneca Stock Topped the Market on Tuesday
    Trading in AstraZeneca's (AZN 2.26%) American Depositary Shares (ADSes) was lively on Tuesday, on news that its leadership intends to directly list its sock on a U.S. exchange. Investors clearly liked that idea, as they bid those ADSes up by more than 2% that trading session.
    07/01 11:13 EST - proactiveinvestors.co.uk
    AstraZeneca shares pop on news CEO wants to move base to US
    AstraZeneca PLC (LSE:AZN) shares spiked higher on Tuesday afternoon on reports that the boss of the UK pharmaceutical giant wants to move the company to the US. CEO Pascal Soriot wants to the FTSE 100's largest company to leave the UK due to his frustration with restrictions on medicines and...
    07/01 09:37 EST - seekingalpha.com
    AstraZeneca: Navigating Challenges Across Geographies Well
    AstraZeneca's price performance YTD exceeds the healthcare sector and broader markets, indicating investors are assuaged regarding concerns across geographies. The company has offered greater clarity on why its under investigation in China, and so far there's reason to believe matters are under...
    07/01 08:26 EST - proactiveinvestors.co.uk
    AstraZeneca's patent headwinds receding as trial data offers excitement
    UBS has maintained its 'buy' recommendation on AstraZeneca PLC (LSE:AZN), setting a 12-month price target of 10,121p, reflecting confidence that a wave of late-stage clinical readouts will provide fresh share-price catalysts after a period dominated by patent expiries and pricing headwinds....
    06/28 06:35 EST - fool.com
    3 No-Brainer Stocks to Buy for Under $100 Right Now
    What's the biggest misconception about investing? The idea that you need a lot of money to get started is certainly a contender.